MedTrace Logo

Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)

NCT03524066 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2019-02-15

No results posted yet for this study

Summary

The aim of the present study is to increase the general understanding of lung PK of selected compounds by sampling epithelial lining fluid ELF and lung tissue.

Conditions

  • Healthy

Interventions

DRUG

Inhalation

Salbutamol(200µg), Salmeterol (50µg) and Fluticasone propionate (500µg) by inhalation

DRUG

Systemic

Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally

OTHER

Bronchoscopy

Bronchoadsorption sample, bronchial brushing, mucosal biopsy, and BAL samples during bronchoscopy

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Fraunhofer-Institute of Toxicology and Experimental Medicine

    lead OTHER

Principal Investigators

  • Jens Hohlfeld, MD · Fraunhofer ITEM

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-10
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03524066 on ClinicalTrials.gov